YAP and the drug resistance highway

Hippo-Independent Activation of YAP by the GNAQ Uveal Melanoma Oncogene through a Trio-Regulated Rho GTPase Signaling Circuitry

(2014) Xiaodong Feng et al.   CANCER CELL

Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer

(2014) Avnish Kapoor et al.   CELL

KRAS and YAP1 Converge to Regulate EMT and Tumor Survival

(2014) Diane D. Shao et al.   CELL

Lessons from the Cancer Genome

(2013) Levi A. Garraway et al.   CELL

Cancer Genome Landscapes

(2013) B. Vogelstein et al.   SCIENCE

Quit your YAPing: a new target for cancer therapy

(2012) B. Z. Stanger   GENES & DEVELOPMENT

Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP

(2012) Y. Liu-Chittenden et al.   GENES & DEVELOPMENT

DNA-Binding Small Molecules as Inhibitors of Transcription Factors

(2012) Chung-Hang Leung et al.   MEDICINAL RESEARCH REVIEWS

The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain

(2012) J. M. Lamar et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

YAP, TAZ, and Yorkie: a conserved family of signal-responsive transcriptional coregulators in animal development and human diseaseThis paper is one of a selection of papers published in this Special Issue, entitled CSBMCB’s 51st Annual Meeting – Epigenetics and Chromatin Dynamics, and has undergone the Journal’s usual peer review process.

(2009) Kainan Wang et al.   Biochemistry and Cell Biology

MEK1 mutations confer resistance to MEK and B-RAF inhibition

(2009) C. M. Emery et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA